The Effect of Hedia Diabetes Assistant on TiMe-in-range in People With Type 1 Diabetes and Sub-Optimal Glycemic Control in France - A Randomised Controlled Trial.

Last updated: June 3, 2025
Sponsor: Hedia ApS
Overall Status: Active - Recruiting

Phase

N/A

Condition

Diabetes Prevention

Diabetes And Hypertension

Diabetes Mellitus, Type 1

Treatment

Hedia Diabetes Assistant

Clinical Study ID

NCT06819306
2024-A02199-38
  • Ages > 18
  • All Genders

Study Summary

The goal of this randomized controlled study is to assess the clinical performance and safety of Hedia Diabetes Assistant in adults with type 1 diabetes and suboptimal glycemic control in France. The main question to answer is:

  • Does Hedia Diabetes Assistant improve glycemic control? Researchers will compare Hedia Diabetes Assistant in addition to standard treatment to standard treatment alone to see if Hedia Diabetes Assistant can improve glycemic control.

Subjects will:

  • Use Hedia Diabetes Assistant in addition to their standard treatment or only use standard treatment for 6 months.

  • Visit the clinic once when they are included into the study and will otherwise be followed remotely.

  • Fill out questionnaires when they are included and after 6 months.

Eligibility Criteria

Inclusion

Inclusion Criteria:

Signed informed consent

  • Aged ≥ 18 years at the time of signing the informed consent

  • Ability to understand, speak and read French fluently

  • Diagnosed with type 1 diabetes > 12 months prior to the day of screening TIR <70% oflast 14 days or HbA1c >53 mmol/mol (7%) measured within the last month

  • Subject must have the cognitive and physical skills to use mobile applications

  • Access to a smartphone with iOS version 16 and up or Android version 12 and up

  • Treated with the same pen-based insulin regimen with basal insulin (insulinglargine, degludec, or detemir) and rapid-acting insulin (insulin aspart, lispro,glulisine) for at least the three preceding months

  • rtCGM use ≥ 1 month from screening date with ≥70% measurements for the last ≥ 14days

  • Willing to use the same type of CGM for the duration of the clinical investigation

  • Willing to be telemonitored during the study period

  • If female participants of childbearing potential; willing to have a pregnancy testperformed and to use a highly effective method of contraception

  • Affiliated to the French social security system

Exclusion

Exclusion Criteria:

  • Use of human insulin or premixed insulin

  • Using a bolus calculator as a part of standard of care treatment at the time ofscreening

  • If the principal investigator deems that subjects are not healthy, not capable ofcompleting the investigation or in other ways deemed unfit for participation in theinvestigation

  • Ongoing participation in other interventional clinical trials or investigationsduring the investigation period if the principal investigator deems this topotentially affect the safety, clinical performance and/or any study outcomes

  • Female who is pregnant, breast-feeding or intends to be pregnant during theinvestigation period

  • Participant under guardianship, conservatorship, safeguard of justice, or any otherlegal protection measure for a vulnerable adult

Study Design

Total Participants: 154
Treatment Group(s): 1
Primary Treatment: Hedia Diabetes Assistant
Phase:
Study Start date:
March 17, 2025
Estimated Completion Date:
December 31, 2025

Study Description

This randomized controlled trial will enroll 154 adults with type 1 diabetes who have suboptimal glycemic control and are treated with multiple daily injections (MDI) of insulin using a pen-based basal-bolus regimen. Subjects must be using a continuous glucose monitor (CGM) as part of their standard care and be telemonitored.

The study will be conducted at multiple centres in France, with each subject followed for a total duration of six months. During this period, they will have one in-person visit and two follow-up assessments conducted via phone. Data will be collected through the telemonitoring platform.

Subjects will be randomly assigned to either the intervention or control group. The intervention group will use the Hedia Diabetes Assistant in addition to their standard treatment for six months, while the control group will continue with their standard treatment.

Connect with a study center

  • Centre Hospitalier Universitaire d'Angers

    Angers,
    France

    Active - Recruiting

  • Hospices Civils de Lyon

    Lyon,
    France

    Active - Recruiting

  • Centre hospitalier universitaire de Nantes

    Nantes,
    France

    Active - Recruiting

  • Centre hospitalier universitaire de Nîmes

    Nîmes,
    France

    Active - Recruiting

  • Hôpital Bichat - Claude-Bernard

    Paris, 75018
    France

    Active - Recruiting

  • Centre hospitalier universitaire de Poitiers

    Poitiers,
    France

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.